https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Cannabidiol - Help and hype in targeting mucosal diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54160 Wed 28 Feb 2024 15:16:56 AEDT ]]> Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35202 Wed 23 Feb 2022 16:07:13 AEDT ]]> Blood-brain barrier disturbances in diabetes-associated dementia: therapeutic potential for cannabinoids https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35136 Wed 10 Nov 2021 15:04:22 AEDT ]]> Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41786 Tue 23 Jan 2024 16:08:35 AEDT ]]> Fluoropolymer Functionalization of Organ-on-Chip Platform Increases Detection Sensitivity for Cannabinoids https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54352 Tue 20 Feb 2024 16:21:02 AEDT ]]> Cannabidiol drug interaction considerations for prescribers and pharmacists https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51187 Tue 09 Jan 2024 11:21:55 AEDT ]]> Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46014 Tue 08 Nov 2022 18:31:13 AEDT ]]> A simple isocratic HPLC method for the quantitation of 17 cannabinoids https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40111 Thu 28 Jul 2022 15:41:22 AEST ]]> Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30941 Sat 24 Mar 2018 07:33:44 AEDT ]]> Can hemp help? Low-THC cannabis and non-THC cannabinoids for the treatment of cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38260 9-tetrahydrocannabinol (∆9-THC). Evidence is emerging for the therapeutic benefits of cannabis in the treatment of neurological and neurodegenerative diseases, with potential efficacy as an analgesic and antiemetic for the management of cancer-related pain and treatment-related nausea and vomiting, respectively. An increasing number of preclinical studies have established that ∆9-THC can inhibit the growth and proliferation of cancerous cells through the modulation of cannabinoid receptors (CB1R and CB2R), but clinical confirmation remains lacking. In parallel, the anti-cancer properties of non-THC cannabinoids, such as cannabidiol (CBD), are linked to the modulation of non-CB1R/CB2R G-protein-coupled receptors, neurotransmitter receptors, and ligand-regulated transcription factors, which together modulate oncogenic signalling and redox homeostasis. Additional evidence has also demonstrated the anti-inflammatory properties of cannabinoids, and this may prove relevant in the context of peritumoural oedema and the tumour immune microenvironment. This review aims to document the emerging mechanisms of anti-cancer actions of non-THC cannabinoids.]]> Mon 29 Jan 2024 17:45:13 AEDT ]]> A randomised controlled trial of vaporised Δ⁹-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36056 Mon 03 Feb 2020 11:52:08 AEDT ]]> Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42761 Fri 02 Sep 2022 08:40:30 AEST ]]> Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32031 Fri 01 Apr 2022 09:23:38 AEDT ]]>